NASDAQ · CVHealthcareElectromedical Equipment

CapsoVision financials

$6.69−3.32%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Q4 '25
Dec 31
Q3 '25
Sep 30
Revenue$3.6M$2.8M$3.9M$3.5M
Gross profit$1.9M$1.3M$2.0M$1.9M
Gross margin51.4%47.6%49.9%54.1%
Operating income-$7.6M-$7.1M-$7.5M-$8.0M
Net income-$7.5M-$7.0M-$7.4M-$7.9M
Net margin−205.4%−251.9%−188.7%−223.9%
Diluted EPS$-0.15$-0.15$-0.16$-0.17
EBITDA-$7.5M-$7.0M-$7.1M-$8.0M
Operating cash flow-$8.4M-$6.1M-$7.7M-$5.7M
Free cash flow-$8.4M-$6.1M-$7.7M-$5.7M
Diluted shares49.9M47.5M47.6M46.2M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30
Cash & equivalents$9.1M$17.9M$10.1M$17.8M
Short-term investments$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00
Total assets$18.6M$25.9M$18.2M$25.7M
Total liabilities$5.4M$5.7M$4.9M$5.2M
Shareholders' equity$13.2M$20.2M$13.3M$20.4M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology